Shots:

• Hologic acquires Biotheranostics to speed up its entry in the oncology market. The transaction is expected to be completed in Feb’2021
• The acquisition will provide Hologic access to Biotheranostics’ CLIA lab and will aid in accelerating market development for novel tests
• The acquisition allows Hologic to leverage commercial capabilities and expertise in molecular diagnostics automation to accelerate growth and deliver more personalized treatment for women

 ­ Ref: Business Wire | Image: Business Wire